Regeneron Rose 3% This Week. Here’s Where the Stock Could Be Headed in 2026

Key Stats for Regeneron Pharmaceuticals Stock

• Past-Week Performance: 3%
• 52-Week Range: $476 to $821
• Valuation Model Target Price: $998
• Implied Upside: 28%

Value your favorite stocks like Regeneron Pharmaceuticals with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>

What Happened?

Regeneron Pharmaceuticals, Inc. stock rose about 3% this week, trading near $780 per share, as shares continued to build on post-earnings momentum. The move reflected improving sentiment following recent analyst actions and ongoing confidence in the company’s earnings durability rather than any single headline.

The stock moved higher this week as renewed analyst support and constructive institutional activity outweighed valuation concerns.

Guggenheim raised its price target on Regeneron to $975 from $865 and reiterated a Buy rating, implying roughly 25% upside from recent levels. The firm cited confidence in Regeneron’s earnings profile and pipeline visibility, which helped drive incremental buying interest.

This week, investors also continued to digest management commentary from the late-January earnings call.

Regeneron reported fourth-quarter revenue of $3.9 billion, up 3% year over year, with adjusted EPS of $11.44, driven by continued strength in DUPIXENT, which generated $4.9 billion in quarterly sales and grew 32%, alongside EYLEA HD U.S. sales of $506 million, up 66%, and LIBTAYO sales of $425 million, up 13%.

CEO Leonard Schleifer described the year ahead as “a busy and ambitious year” as the company advances multiple late-stage programs.

Institutional activity remained broadly constructive. Candriam S.C.A. increased its stake by 19% to 169,495 shares worth about $95 million, while Bessemer Group, Savant Capital, Prime Capital Investment Advisors, and Murphy Pohlad Asset Management all meaningfully increased positions during the quarter.

Although Thrivent Financial trimmed its stake by about 21%, overall institutional ownership remained high at roughly 83%, reinforcing long-term conviction.

See analysts’ growth forecasts and price targets for Regeneron Pharmaceuticals (It’s free) >>>

Is Regeneron Pharmaceuticals Undervalued?

Under valuation assumptions, the stock is modeled using:

• Revenue Growth (CAGR): 9.2%
• Operating Margins: 37.0%
• Exit P/E Multiple: 15.4x

Revenue growth reflects Regeneron’s transition toward a more diversified growth profile as newer therapies scale and offset slower growth in mature products.

Continued expansion from DUPIXENT, EYLEA HD, and LIBTAYO, alongside contributions from newer launches, supports steady top-line growth without reliance on a single product cycle.

Earnings quality remains the more important driver. Regeneron’s margin structure benefits from biologics pricing power, disciplined R&D deployment, and a commercial mix skewed toward high-value therapies, allowing profits to compound faster than revenue as newer programs mature.

This supports the view that future returns depend more on durable margins, pipeline execution, and incremental earnings contributions than on aggressive revenue acceleration.

With operating leverage already in place, even moderate growth can translate into meaningful earnings expansion.

Results over the next year hinge on execution across several higher-impact areas. Regulatory milestones, late-stage clinical readouts, and commercial uptake from recent launches carry the most weight, as successful outcomes could further diversify revenue and reduce product concentration risk.

At current levels, Regeneron appears undervalued, with future performance driven by pipeline progress, sustained biologics margins, and earnings quality rather than multiple expansion alone.

Estimate a company’s fair value instantly (Free with TIKR) >>>

Value Any Stock in Under 60 Seconds (It’s Free)

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>